Skip to content
2000
image of Lifileucel Therapy for Metastatic Melanoma: Advancements in Tumor-infiltrating Lymphocyte-based Immunotherapy

Abstract

Metastatic melanoma is an aggressive malignancy with limited treatment options at advanced stages. Lifileucel, an FDA-approved autologous Tumor-Infiltrating Lymphocyte (TIL) therapy, marks a major advancement in immunotherapy, particularly for patients who fail conventional treatments like immune checkpoint inhibitors and targeted therapies. The mechanism of lifileucel involves the expansion of patient-derived TILs to boost immune responses against melanoma cells. These expanded TILs are re-infused into patients, enhancing tumor-specific cytotoxicity and modulating the tumor microenvironment for sustained immune activation. Clinical trials have demonstrated its efficacy, with the overall response rate (ORR) reaching up to 36% in heavily pretreated populations, offering durable responses and improved progression-free survival compared to traditional therapies. The personalized approach of lifileucel, leveraging the patient’s own T-cell repertoire, highlights its potential for precision oncology by targeting individual tumor profiles. Its integration with combination therapies, particularly immune checkpoint inhibitors, shows promising synergistic effects, broadening its clinical applicability. In addition to clinical success, the role of lifileucel in influencing the melanogenesis pathway offers insights into optimizing therapeutic strategies for melanoma. Ongoing research focuses on enhancing TIL functionality, overcoming challenges like tumor-induced immune suppression, and extending the applicability of lifileucel to other solid tumors. This breakthrough therapy not only addresses a critical unmet need in melanoma treatment but also represents a paradigm shift toward personalized medicine in oncology. Lifileucel underscores the potential of TIL-based approaches to revolutionize cancer care, setting the stage for future advancements in immunotherapy.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/acamc/10.2174/0118715206380598250622182719
2025-07-04
2025-12-08

  • From This Site

    /content/journals/acamc/10.2174/0118715206380598250622182719
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Johansson M. Brodersen J. Jørgensen K.J. Screening for reducing morbidity and mortality in malignant melanoma. Cochrane Database Syst. Rev. 2019 6 6 CD012352 10.1002/14651858.CD012352.pub2 31157404
    [Google Scholar]
  2. Wunderlich K. Suppa M. Gandini S. Lipski J. White J.M. Del Marmol V. Risk factors and innovations in risk assessment for melanoma, basal cell carcinoma, and squamous cell carcinoma. Cancers 2024 16 5 1016 10.3390/cancers16051016 38473375
    [Google Scholar]
  3. Carlino M.S. Larkin J. Long G.V. Immune checkpoint inhibitors in melanoma. Lancet 2021 398 10304 1002 1014 10.1016/S0140‑6736(21)01206‑X 34509219
    [Google Scholar]
  4. Switzer B. Puzanov I. Skitzki J.J. Hamad L. Ernstoff M.S. Managing metastatic melanoma in 2022: A clinical review. JCO Oncol. Pract. 2022 18 5 335 351 10.1200/OP.21.00686 35133862
    [Google Scholar]
  5. Haist M. Stege H. Ebner R. Fleischer M.I. Loquai C. Grabbe S. The role of treatment sequencing with immune-checkpoint inhibitors and BRAF/MEK inhibitors for response and survival of patients with BRAFV600-mutant metastatic melanoma—a retrospective, real-world cohort study. Cancers 2022 14 9 2082 10.3390/cancers14092082 35565212
    [Google Scholar]
  6. Lopes J. Rodrigues C.M.P. Gaspar M.M. Reis C.P. Melanoma management: From epidemiology to treatment and latest advances. Cancers 2022 14 19 4652 10.3390/cancers14194652 36230575
    [Google Scholar]
  7. Imani S. Roozitalab G. Emadi M. Moradi A. Behzadi P. Jabbarzadeh Kaboli P. The evolution of BRAF-targeted therapies in melanoma: overcoming hurdles and unleashing novel strategies. Front. Oncol. 2024 14 1504142 10.3389/fonc.2024.1504142 39582535
    [Google Scholar]
  8. Ribas A. Lawrence D. Atkinson V. Agarwal S. Miller W.H. Carlino M.S. Fisher R. Long G.V. Hodi F.S. Tsoi J. Grasso C.S. Mookerjee B. Zhao Q. Ghori R. Moreno B.H. Ibrahim N. Hamid O. Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma. Nat. Med. 2019 25 6 936 940 10.1038/s41591‑019‑0476‑5 31171879
    [Google Scholar]
  9. Chesney J. Lewis K.D. Kluger H. Hamid O. Whitman E. Thomas S. Wermke M. Cusnir M. Domingo-Musibay E. Phan G.Q. Kirkwood J.M. Hassel J.C. Orloff M. Larkin J. Weber J. Furness A.J.S. Khushalani N.I. Medina T. Egger M.E. Graf Finckenstein F. Jagasia M. Hari P. Sulur G. Shi W. Wu X. Sarnaik A. Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: Pooled analysis of consecutive cohorts of the C-144-01 study. J. Immunother. Cancer 2022 10 12 e005755 10.1136/jitc‑2022‑005755 36600653
    [Google Scholar]
  10. Thomas S.S. Gogas H. Hong Y.K. In, G.K.; Doger de Spéville Uribe, B.; Furness, A.J.S.; García Castaño, A.; Haefliger, S.; He, K.; Medina, T.; Lawrence, D.; Lee, S.; Martin-Liberal, J.; Graf Finckenstein, F.; Gastman, B.; Chou, J.; Fiaz, R.; Catlett, M.; Chen, G.; Terheyden, P. Efficacy and safety of lifileucel, an autologous tumor-infiltrating lymphocyte cell therapy, and pembrolizumab in patients with immune checkpoint inhibitor-naive unresectable or metastatic melanoma: Updated results from IOV-COM-202 cohort 1A. J. Clin. Oncol. 2024 42 16 Suppl. 9505 10.1200/JCO.2024.42.16_suppl.9505
    [Google Scholar]
  11. Keam S.J. Lifileucel: First approval. Mol. Diagn. Ther. 2024 28 3 339 344 10.1007/s40291‑024‑00708‑y 38625642
    [Google Scholar]
  12. de Oliveira G.A.F. de Oliveira D.A. Nisimoto M.Y.S.M. Rubinho R. Gomes H.C. Marti L.C. de Oliveira Filho R.S. Advances in Tumor-Infiltrating Lymphocyte (TIL) as a prognostic factor and for treating invasive cutaneous melanoma. Int. J. Mol. Sci. 2024 25 23 12596 10.3390/ijms252312596 39684307
    [Google Scholar]
  13. Jiménez-Reinoso A. Molero-Abraham M. Cirauqui C. Blanco B. Garrido-Martin E.M. Nehme-Álvarez D. Domínguez-Alonso C. Ramírez-Fernández Á. Díez-Alonso L. Nuñez-Buiza Á. González-Murillo Á. Tobes R. Pareja E. Ramírez-Orellana M. Rodriguez-Peralto J.L. Ferrer I. Zugazagoitia J. Paz-Ares L. Álvarez-Vallina L. CD4+ tumor-infiltrating lymphocytes secreting T cell-engagers induce regression of autologous patient-derived non-small cell lung cancer xenografts. OncoImmunology 2024 13 1 2392897 10.1080/2162402X.2024.2392897 39206095
    [Google Scholar]
  14. Betof Warner A. Hamid O. Komanduri K. Amaria R. Butler M.O. Haanen J. Nikiforow S. Puzanov I. Sarnaik A. Bishop M.R. Schoenfeld A.J. Expert consensus guidelines on management and best practices for tumor-infiltrating lymphocyte cell therapy. J. Immunother. Cancer 2024 12 2 e008735 10.1136/jitc‑2023‑008735 38423748
    [Google Scholar]
  15. Julve M. Furness A.J.S. Advances in the development of tumor-infiltrating lymphocyte therapy for advanced melanoma. Expert Opin. Biol. Ther. 2023 23 4 319 323 10.1080/14712598.2023.2193290 36932721
    [Google Scholar]
  16. Vishakha S. Navneesh N. Kurmi B.D. Das Gupta G. Verma S.K. Jain A. Patel P. An expedition on synthetic methodology of FDA-approved anticancer drugs (2018-2021). Anticancer. Agents Med. Chem. 2024 24 8 590 626 10.2174/0118715206259585240105051941 38288815
    [Google Scholar]
  17. Betof Warner A. Corrie P.G. Hamid O. Tumor-infiltrating lymphocyte therapy in melanoma: Facts to the future. Clin. Cancer Res. 2023 29 10 1835 1854 10.1158/1078‑0432.CCR‑22‑1922 36485001
    [Google Scholar]
  18. Dafni U. Michielin O. Lluesma S.M. Tsourti Z. Polydoropoulou V. Karlis D. Besser M.J. Haanen J. Svane I.M. Ohashi P.S. Kammula U.S. Orcurto A. Zimmermann S. Trueb L. Klebanoff C.A. Lotze M.T. Kandalaft L.E. Coukos G. Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: A systematic review and meta-analysis. Ann. Oncol. 2019 30 12 1902 1913 10.1093/annonc/mdz398 31566658
    [Google Scholar]
  19. Majidpoor J. Mortezaee K. Interleukin-2 therapy of cancer-clinical perspectives. Int. Immunopharmacol. 2021 98 107836 10.1016/j.intimp.2021.107836 34218217
    [Google Scholar]
  20. Julve M. Wong Y.N.S. Lim K.H.J. Furness A.J.S. Solid tumour cellular therapy — Principles of toxicity management. Immunooncol. Technol 2024 100737 10.1016/j.iotech.2024.100737
    [Google Scholar]
  21. Haanen J. Los C. Phan G.Q. Betof Warner A. Adoptive cell therapy for solid tumors: Current status in melanoma and next-generation therapies. Am. Soc. Clin. Oncol. Educ. Book 2024 44 3 e431608 10.1200/EDBK_431608 38776509
    [Google Scholar]
  22. Wagner D.L. Fritsche E. Pulsipher M.A. Ahmed N. Hamieh M. Hegde M. Ruella M. Savoldo B. Shah N.N. Turtle C.J. Wayne A.S. Abou-el-Enein M. Immunogenicity of CAR T cells in cancer therapy. Nat. Rev. Clin. Oncol. 2021 18 6 379 393 10.1038/s41571‑021‑00476‑2 33633361
    [Google Scholar]
  23. Shah N.N. Fry T.J. Mechanisms of resistance to CAR T cell therapy. Nat. Rev. Clin. Oncol. 2019 16 6 372 385 10.1038/s41571‑019‑0184‑6 30837712
    [Google Scholar]
  24. Betof Warner A. Smithy J.W. Postow M.A. Panageas K. Schoenfeld A.J. Wolchok J.D. A pilot trial of autologous tumor infiltrating lymphocytes (lifileucel, LN-144) for patients with asymptomatic melanoma brain metastases. J. Clin. Oncol. 2024 42 16 Suppl. TPS9603 10.1200/JCO.2024.42.16_suppl.TPS9603
    [Google Scholar]
  25. Talty R. Richmond R. Micevic G. Melanoma tumour-infiltrating T-lymphocyte therapy heralds the era of cell-based immunotherapies for solid tumours. Br. J. Dermatol. 2024 190 6 779 781 10.1093/bjd/ljae126
    [Google Scholar]
  26. Sarnaik A. Khushalani N. Chesney J. Kluger H. Curti B. Lewis K. Safety & efficacy of lifileucel (LN-144) tumor infiltrating lymphocyte therapy in metastatic melanoma patients after progression on multiple therapies – Independent review committee data update. J. Immunother Cancer 2020 8 Suppl 1 10.1136/LBA2019.18
    [Google Scholar]
  27. Nassief G. Anaeme A. Moussa K. Mansour A. Ansstas G. Recent advancements in cell-based therapies in melanoma. Int. J. Mol. Sci. 2024 25 18 9848 10.3390/ijms25189848 39337333
    [Google Scholar]
  28. Klobuch S. Seijkens T.T.P. Schumacher T.N. Haanen J.B.A.G. Tumour-infiltrating lymphocyte therapy for patients with advanced-stage melanoma. Nat. Rev. Clin. Oncol. 2024 21 3 173 184 10.1038/s41571‑023‑00848‑w 38191921
    [Google Scholar]
  29. Mahuron K. Fong Y. Chapter 6-Tumor-infiltrating lymphocyte (TIL) therapy. In: NK Cells in Cancer Immunotherapy: Successes and Challenges. Chapter 6 Academic Press 2023 133 147 10.1016/B978‑0‑12‑822620‑9.00026‑4
    [Google Scholar]
  30. Fateeva A. Eddy K. Chen S. Current state of melanoma therapy and next steps: Battling therapeutic resistance. Cancers 2024 16 8 1571 10.3390/cancers16081571 38672652
    [Google Scholar]
  31. Ascierto P.A. Lipson E.J. Dummer R. Larkin J. Long G.V. Sanborn R.E. Chiarion-Sileni V. Dréno B. Dalle S. Schadendorf D. Callahan M.K. Nyakas M. Atkinson V. Gomez-Roca C.A. Yamazaki N. Tawbi H.A. Sarkis N. Warad D. Dolfi S. Mitra P. Suryawanshi S. Grob J.J. Nivolumab and relatlimab in patients with advanced melanoma that had progressed on anti–programmed death-1/programmed death ligand 1 therapy: Results from the phase I/IIa RELATIVITY-020 trial. J. Clin. Oncol. 2023 41 15 2724 2735 10.1200/JCO.22.02072 36780608
    [Google Scholar]
  32. Mushtaq M.U. Abdelhakim H. Selby L. Abhyankar S.H. McGuirk J. Doolittle G.C. Reduced dose fludarabine/cyclophosphamide lymphodepletion for tumor-infiltrating lymphocytes therapy (LN-144, lifileucel) in metastatic melanoma. J. Clin. Oncol. 2024 42 16 Suppl. 10.1200/JCO.2024.42.16_suppl.TPS9608
    [Google Scholar]
  33. Filin I.Y. Mayasin Y.P. Kharisova C.B. Gorodilova A.V. Kitaeva K.V. Chulpanova D.S. Solovyeva V.V. Rizvanov A.A. Cell immunotherapy against melanoma: Clinical trials Review. Int. J. Mol. Sci. 2023 24 3 2413 10.3390/ijms24032413 36768737
    [Google Scholar]
  34. Natarelli N. Aleman S.J. Mark I.M. Tran J.T. Kwak S. Botto E. Aflatooni S. Diaz M.J. Lipner S.R. A review of current and pipeline drugs for treatment of melanoma. Pharmaceuticals 2024 17 2 214 10.3390/ph17020214 38399429
    [Google Scholar]
  35. Medina T. Chesney J.A. Whitman E. Kluger H. Thomas S. Sarnaik A. Kirkwood J.M. Larkin J. Weber J.S. Hamid O. Wermke M. Finckenstein F.G. Chou J. Gastman B. Sulur G. Wu X. Shi W. Domingo-Musibay E. 119O Long-term efficacy and patterns of response of lifileucel tumor-infiltrating lymphocyte (TIL) cell therapy in patients with advanced melanoma: A 4-year analysis of the C-144-01 study. Immunooncol Technol 2023 20 100591 10.1016/j.iotech.2023.100591
    [Google Scholar]
  36. van Asten S.D. de Groot R. van Loenen M.M. Castenmiller S.M. de Jong J. Monkhorst K. Haanen J.B.A.G. Amsen D. Bex A. Spaapen R.M. Wolkers M.C. T cells expanded from renal cell carcinoma display tumor-specific CD137 expression but lack significant IFN-γ, TNF-α or IL-2 production. OncoImmunology 2021 10 1 1860482 10.1080/2162402X.2020.1860482 33537169
    [Google Scholar]
  37. Falcone I. Conciatori F. Bazzichetto C. Ferretti G. Cognetti F. Ciuffreda L. Milella M. Tumor microenvironment: Implications in melanoma resistance to targeted therapy and immunotherapy. Cancers (Basel) 2020 12 10 2870 10.3390/cancers12102870 33036192
    [Google Scholar]
  38. Einstein D.J. Halbert B. Denize T. Matar S. West D.J. Gupta M. Andrianopoulos E. Seery V. Herman C. Onimus K. Wells A. Bunch B. Signoretti S. Natarajan A. Veerapathran A. McDermott D.F. Generation and characterization of ex vivo expanded tumor-infiltrating lymphocytes from renal cell carcinoma tumors for adoptive cell therapy. J. Immunother. 2024 47 9 361 368 10.1097/CJI.0000000000000533 38995718
    [Google Scholar]
  39. Hall M.S. Mullinax J.E. Cox C.A. Hall A.M. Beatty M.S. Blauvelt J. Innamarato P. Nagle L. Branthoover H. Wiener D. Schachner B. Martinez A.J. Richards A.D. Rich C.J. Colón Colón M. Schell M.J. Teer J.K. Khushalani N.I. Weber J.S. Mulé J.J. Sondak V.K. Pilon-Thomas S. Sarnaik A.A. Combination nivolumab, CD137 agonism, and adoptive cell therapy with tumor-infiltrating lymphocytes for patients with metastatic melanoma. Clin. Cancer Res. 2022 28 24 5317 5329 10.1158/1078‑0432.CCR‑22‑2103 36215121
    [Google Scholar]
  40. Hamid O. Tumor-infiltrating lymphocyte therapy advances into melanoma. Oncology 2024 38 4
    [Google Scholar]
  41. Trojaniello C. Luke J.J. Ascierto P.A. Therapeutic advancements across clinical stages in melanoma, with a focus on targeted immunotherapy. Front. Oncol. 2021 11 670726 10.3389/fonc.2021.670726 34178657
    [Google Scholar]
  42. Parra L.M. Webster R.M. The malignant melanoma market. Nat. Rev. Drug Discov. 2022 21 7 489 490 10.1038/d41573‑022‑00075‑5 35477778
    [Google Scholar]
  43. O’Malley D. Lee S. Psyrri A. Sukari A. Thomas S. Wenham R. R. 492 Phase 2 efficacy and safety of autologous tumor-infiltrating lymphocyte (TIL) cell therapy in combination with pembrolizumab in immune checkpoint inhibitor-naïve patients with advanced cancers. J. Immunother Cancer 2021 9 Suppl 2 10.1136/jitc‑2021‑SITC2021.492
    [Google Scholar]
  44. Knight A.D. Luke J.J. Beyond immune checkpoint inhibitors: Emerging targets in melanoma therapy. Curr. Oncol. Rep. 2024 26 7 826 839 10.1007/s11912‑024‑01551‑4 38789670
    [Google Scholar]
  45. Switzer B. Piperno-Neumann S. Lyon J. Buchbinder E. Puzanov I. Evolving management of stage IV melanoma. Am. Soc. Clin. Oncol. Educ. Book 2023 43 43 e397478 10.1200/EDBK_397478 37141553
    [Google Scholar]
  46. Chan P.Y. Corrie P.G. Curing stage IV melanoma: Where have we been and where are we? Am. Soc. Clin. Oncol. Educ. Book 2024 44 3 e438654 10.1200/EDBK_438654 38669609
    [Google Scholar]
  47. Rosa K. Consistent durable responses are observed for lifileucel in melanoma regardless of IL-2 doses. Target Ther. Oncol. 2023 12 3
    [Google Scholar]
  48. Rokade S. Damani A.M. Oft M. Emmerich J. IL-2 based cancer immunotherapies: An evolving paradigm. Front. Immunol. 2024 15 1433989 10.3389/fimmu.2024.1433989 39114660
    [Google Scholar]
  49. Costa M. 2021 ASCO Virtual Annual Meeting. Lancet Oncol. 2021 22 7 912 913 10.1016/S1470‑2045(21)00338‑7 34118997
    [Google Scholar]
  50. Brudno J.N. Maus M.V. Hinrichs C.S. CAR T cells and T-cell therapies for cancer. JAMA 2024 332 22 1924 1935 10.1001/jama.2024.19462 39495525
    [Google Scholar]
  51. Lee H. Kim K. Chung J. Hossain M. Lee H.J. Tumor‐infiltrating lymphocyte therapy: Clinical aspects and future developments in this breakthrough cancer treatment. BioEssays 2023 45 7 2200204 10.1002/bies.202200204 37166068
    [Google Scholar]
  52. Galvagno F. Experimental models of CAR-redirected cellular therapy with CIK lymphocytes against ovarian cancer peritoneal carcinomatosis. Doctor of Philosophy. Università di Torino 2024
    [Google Scholar]
  53. Voorhees T.J. Bezerra E. Denlinger N. Jaglowski S. de Lima M. SOHO state of the art updates and next questions updates on building your CAR-T cell program. Clin. Lymphoma Myeloma Leuk. 2024 24 10 649 652 10.1016/j.clml.2024.03.007 38643029
    [Google Scholar]
  54. Singh K. Rocco J.M. Nussenblatt V. The winding road: Infectious disease considerations for CAR-T and other novel adoptive cellular therapies in the era of COVID-19. Semin. Hematol. 2024 61 5 321 332 10.1053/j.seminhematol.2024.08.002
    [Google Scholar]
  55. Shebrain A. Idris O.A. Jawad A. Zhang T. Xing Y. Advancements and challenges in personalized therapy for BRAF-mutant melanoma: A comprehensive review. J. Clin. Med. 2024 13 18 5409 10.3390/jcm13185409 39336897
    [Google Scholar]
  56. Weiser P. FDA accepts BLA for lifileucel for difficult-to-treat melanoma. In: Formulary Watch 2023
    [Google Scholar]
  57. Wang W. Navigating Challenges in Cell Therapy Potency Assays: Developing cell-based potency assays for cell therapies requires meticulous coordination. LC GC Eur. 2024 37 1 31 34
    [Google Scholar]
  58. Kanate A.S. Majhail N. DeFilipp Z. Dhakal B. Dholaria B. Hamilton B. Herrera A.F. Inamoto Y. Jain T. Perales M.A. Carpenter P.A. Hamadani M. Updated indications for immune effector cell therapy: 2023 guidelines from the American Society for Transplantation and Cellular Therapy. Transplant. Cell. Ther. 2023 29 10 594 597 10.1016/j.jtct.2023.07.002 37422194
    [Google Scholar]
  59. Khattak M.A. Luke J.J. Top advances of the year: Melanoma. Cancer 2024 130 16 2733 2738 10.1002/cncr.35354
    [Google Scholar]
  60. Mooradian M.J. Sullivan R.J. Immunotherapy in melanoma: Recent advancements and future directions. Cancers 2023 15 16 4176 10.3390/cancers15164176 37627204
    [Google Scholar]
  61. Monk B.J. Enomoto T. Kast W.M. McCormack M. Tan D.S.P. Wu X. González-Martín A. Integration of immunotherapy into treatment of cervical cancer: Recent data and ongoing trials. Cancer Treat. Rev. 2022 106 102385 10.1016/j.ctrv.2022.102385 35413489
    [Google Scholar]
  62. Bulliard Y. Freeborn R. Uyeda M.J. Humes D. Bjordahl R. de Vries D. From promise to practice: CAR T and Treg cell therapies in autoimmunity and other immune-mediated diseases. Front. Immunol. 2024 15 1509956 10.3389/fimmu.2024.1509956 39697333
    [Google Scholar]
  63. World’s first TIL therapy approved. Nat. Biotechnol. 2024 42 3 349 10.1038/s41587‑024‑02195‑2
    [Google Scholar]
  64. Ascierto P.A. Agarwala S.S. Warner A.B. Ernstoff M.S. Fox B.A. Gajewski T.F. Galon J. Garbe C. Gastman B.R. Gershenwald J.E. Kalinski P. Krogsgaard M. Leidner R.S. Lo R.S. Menzies A.M. Michielin O. Poulikakos P.I. Weber J.S. Caracò C. Osman I. Puzanov I. Thurin M. Perspectives in melanoma: Meeting report from the melanoma bridge (December 1st–3rd, 2022—Naples, Italy). J. Transl. Med. 2023 21 1 508 10.1186/s12967‑023‑04325‑x 37507765
    [Google Scholar]
  65. Verdegaal E. van der Kooij M.K. Visser M. van der Minne C. de Bruin L. Meij P. Terwisscha van Scheltinga A. Welters M.J. Santegoets S. de Miranda N. Roozen I. Liefers G.J. Kapiteijn E. van der Burg S.H. Low-dose interferon-alpha preconditioning and adoptive cell therapy in patients with metastatic melanoma refractory to standard (immune) therapies: A phase I/II study. J. Immunother. Cancer 2020 8 1 e000166 10.1136/jitc‑2019‑000166 32238469
    [Google Scholar]
  66. Amaral T. Ottaviano M. Arance A. Blank C. Chiarion-Sileni V. Donia M. Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann. Oncol. 2024 36 1 10 30 10.1016/j.annonc.2024.11.006 39550033
    [Google Scholar]
  67. Medina T. Chesney J.A. Whitman E. Kluger H. Thomas S. Sarnaik A.A. 776 Long-term efficacy and safety of lifileucel tumor- infiltrating lymphocyte (TIL) cell therapy in patients with advanced melanoma: A 4-year analysis of the C-144–01 study. J. Immunother Cancer 2023 11 Suppl 1 10.1136/jitc‑2023‑SITC2023.0776
    [Google Scholar]
  68. Namikawa K. Nakano E. Ogata D. Yamazaki N. Long‐term survival with systemic therapy in the last decade: Can melanoma be cured? J. Dermatol. 2024 51 3 343 352 10.1111/1346‑8138.17147 38358050
    [Google Scholar]
  69. Nemunaitis J. Stanbery L. Willoughby D. Bognar E. Brun S. Walter A. Monk B.J. Rocconi R.P. Choucair K. Coleman R.L. Clonal neoantigen: Emerging “mechanism-based” biomarker of immunotherapy response. Cancers 2023 15 23 5616 10.3390/cancers15235616 38067319
    [Google Scholar]
  70. Slominski R.M. Kim T.K. Janjetovic Z. Brożyna A.A. Podgorska E. Dixon K.M. Mason R.S. Tuckey R.C. Sharma R. Crossman D.K. Elmets C. Raman C. Jetten A.M. Indra A.K. Slominski A.T. Malignant melanoma: An overview, new perspectives, and vitamin D signaling. Cancers 2024 16 12 2262 10.3390/cancers16122262 38927967
    [Google Scholar]
  71. Boretti A. Improving chimeric antigen receptor T-cell therapies by using artificial intelligence and internet of things technologies: A narrative review. Eur. J. Pharmacol. 2024 974 176618 10.1016/j.ejphar.2024.176618 38679117
    [Google Scholar]
  72. Dandoy C.E. Adams J. Artz A. Bredeson C. Dahi P.B. Dodd T. In Pursuit of optimal outcomes: A framework for quality standards in immune effector cell therapy. Transplant. Cell. Ther. 2024 30 1 942 954 10.1016/j.jtct.2024.07.011
    [Google Scholar]
  73. Lau P.K.H. Cullinane C. Jackson S. Walker R. Smith L.K. Slater A. Kirby L. Patel R.P. von Scheidt B. Slaney C.Y. McArthur G.A. Sheppard K.E. Enhancing adoptive cell transfer with combination BRAF-MEK and CDK4/6 inhibitors in melanoma. Cancers 2021 13 24 6342 10.3390/cancers13246342 34944961
    [Google Scholar]
  74. Kazemi M.H. Sadri M. Najafi A. Rahimi A. Baghernejadan Z. Khorramdelazad H. Falak R. Tumor-infiltrating lymphocytes for treatment of solid tumors: It takes two to tango? Front. Immunol. 2022 13 1018962 10.3389/fimmu.2022.1018962 36389779
    [Google Scholar]
  75. Wang J. Zhang B. Peng L. Liu X. Sun J. Su C. Wang H. Zhao Z. Si L. Duan J. Zhang H. Li M. Zhu B. Zhang L. Li J. Guo J. Luo R. Qiu W. Ye D. Chu Q. Cui J. Dong X. Fan Y. Gao Q. Guo Y. He Z. Li W. Lin G. Liu L. Liu Y. Qin H. Ren S. Ren X. Wang Y. Xue J. Yang Y. Yang Z. Yue L. Zhan X. Zhang J. Ma J. Qin S. Wang B. Chinese expert consensus recommendations for the administration of immune checkpoint inhibitors to special cancer patient populations. Ther. Adv. Med. Oncol. 2023 15 17588359231187205 10.1177/17588359231187205 37484525
    [Google Scholar]
  76. Chesney J.A. Larkin J.M. Kirkwood J.M. Weber J.S. Khushalani N.I. Lewis K. Lifileucel (LN-144), a cryopreserved autologous tumor infiltrating lymphocyte (TIL) therapy in patients with advanced (unresectable or metastatic) melanoma: Sustained duration of response at 28 month follow up. 2021 Available from: https://www.iovance.com/uploads/AACR21_C-144-01_Long-Term-Follow-Up_Chesney_2021-03-18.pdf
    [Google Scholar]
  77. Augustin R.C. Luke J.J. Top advances of the year: Melanoma. Cancer 2023 129 6 822 828 10.1002/cncr.34590 36629350
    [Google Scholar]
  78. Locke F.L. olid tumor TIL therapy is infiltrating multiple centers with lympho-“sights” set on becoming standard of care Hematologist 2022 19 1 10.1182/hem.V19.1.2022115
    [Google Scholar]
  79. Kuznar W. Unique immunotherapy combos evaluated in advanced melanoma. Target Ther. Oncol. 2021 10 10
    [Google Scholar]
  80. Martín-Lluesma S. Svane I.M. Dafni U. Vervita K. Karlis D. Dimopoulou G. Tsourti Z. Rohaan M.W. Haanen J.B.A.G. Coukos G. Efficacy of TIL therapy in advanced cutaneous melanoma in the current immuno-oncology era: Updated systematic review and meta-analysis. Ann. Oncol. 2024 35 10 860 872 10.1016/j.annonc.2024.07.723 39053767
    [Google Scholar]
  81. Kahn A.M. Perry C.J. Etts K. Kluger H. Sznol M. Clinical predictors of survival in patients with BRAFV600-mutated metastatic melanoma treated with combined BRAF and MEK inhibitors after immune checkpoint inhibitors. Oncologist 2024 29 4 e507 e513 10.1093/oncolo/oyad300 37971411
    [Google Scholar]
  82. Yu C. Li Q. Zhang Y. Wen Z.F. Dong H. Mou Y. Current status and perspective of tumor immunotherapy for head and neck squamous cell carcinoma. Front. Cell Dev. Biol. 2022 10 941750 10.3389/fcell.2022.941750 36092724
    [Google Scholar]
  83. Butterfield L.H. Najjar Y.G. Immunotherapy combination approaches: Mechanisms, biomarkers and clinical observations. Nat. Rev. Immunol. 2024 24 6 399 416 10.1038/s41577‑023‑00973‑8 38057451
    [Google Scholar]
  84. Zheng D.X. Jenkins R.W. Real-world data confirms limited efficacy of dual anti-PD-1 and CTLA-4 immune checkpoint blockade in acral lentiginous melanoma. Br. J. Dermatol. 2024 192 2 186 187
    [Google Scholar]
  85. Schoenfeld A.J. Lee S.M. Doger de Spéville B. Gettinger S.N. Häfliger S. Sukari A. Papa S. Rodríguez-Moreno J.F. Graf Finckenstein F. Fiaz R. Catlett M. Chen G. Qi R. Masteller E.L. Gontcharova V. He K. Lifileucel, an autologous tumor-infiltrating lymphocyte monotherapy, in patients with advanced non–small cell lung cancer resistant to immune checkpoint inhibitors. Cancer Discov. 2024 14 8 1389 1402 10.1158/2159‑8290.CD‑23‑1334 38563600
    [Google Scholar]
  86. Thomas S.S. In G.K. Doger B. Haefliger S. Martin-Liberal J. Goldberg Z. Safety and efficacy of lifileucel (LN-144), an autologous, tumor infiltrating lymphocyte cell therapy in combination with pembrolizumab for immune checkpoint inhibitor naïve patients with advanced melanoma. In: J. Clin. Oncol; 2021 39 15_suppl 10.1200/JCO.2021.39.15_suppl.9537
    [Google Scholar]
  87. Gettinger S. Kluger H. Schoenfeld A. Warner A.B. He K. Sukari A. Thomas S. Doger B. Lee S. Haefliger S. Goldberg Z. Cacovean A. Fiaz R. Chen G. Jagasia M. Finckenstein F.G. Fardis M. Jimeno A. P14.05 phase 2, study of iovance autologous tumor infiltrating lymphocytes (lifileucel, LN-144, LN-145, LN-145-S1) in patients with solid tumors. J. Thorac. Oncol. 2021 16 10 S1012 S1013 10.1016/j.jtho.2021.08.335
    [Google Scholar]
  88. Slominski R.M. Sarna T. Płonka P.M. Raman C. Brożyna A.A. Slominski A.T. Melanoma, melanin, and melanogenesis: The Yin and Yang relationship. Front. Oncol. 2022 12 842496 10.3389/fonc.2022.842496 35359389
    [Google Scholar]
  89. Kim H.J. Kim Y.H. Molecular frontiers in melanoma: Pathogenesis, diagnosis, and therapeutic advances. Int. J. Mol. Sci. 2024 25 5 2984 10.3390/ijms25052984 38474231
    [Google Scholar]
  90. Zhou S. Zeng H. Huang J. Lei L. Tong X. Li S. Zhou Y. Guo H. Khan M. Luo L. Xiao R. Chen J. Zeng Q. Epigenetic regulation of melanogenesis. Ageing Res. Rev. 2021 69 101349 10.1016/j.arr.2021.101349 33984527
    [Google Scholar]
  91. Kamiński K. Kazimierczak U. Kolenda T. Oxidative stress in melanogenesis and melanoma development. Contemp. Oncol. 2022 26 1 1 7 10.5114/wo.2021.112447
    [Google Scholar]
  92. Carpenter E.L. Regulation of redox homeostasis in skin cells for the prevention of UV-induced stress and treatment of melanoma. Doctor of Philosophy. Oregon State University 2022
    [Google Scholar]
  93. Volety P. Shirley C.A. Chhabra G. Ahmad N. The fusion of light and immunity: Advancements in photoimmunotherapy for melanoma. Photochem. Photobiol. 2024 100 4 910 922 10.1111/php.13951 38623955
    [Google Scholar]
  94. Anaya-Prado R. Hernández-González H. Campo A. Anaya-Fernández M. Azcona-Ramírez C. Anaya-Fernández R. Urueta-Chávez B. Méndez-Bisgaard L. Delgado-Vázquez J. García-Romero A. Melanoma: A therapeutic revolution happening before our eyes. Med. Res. Arch. 2022 10 7 10.18103/mra.v10i7.2848
    [Google Scholar]
  95. Qin Z. Zheng M. Advances in targeted therapy and immunotherapy for melanoma (Review). Exp. Ther. Med. 2023 26 3 416 10.3892/etm.2023.12115 37559935
    [Google Scholar]
  96. Truex N.L. Rondon A. Rössler S.L. Hanna C.C. Cho Y. Wang B.Y. Backlund C.M. Lutz E.A. Irvine D.J. Pentelute B.L. Enhanced vaccine immunogenicity enabled by targeted cytosolic delivery of tumor antigens into dendritic cells. ACS Cent. Sci. 2023 9 9 1835 1845 10.1021/acscentsci.3c00625 37780364
    [Google Scholar]
  97. Castellani G. Buccarelli M. Arasi M.B. Rossi S. Pisanu M.E. Bellenghi M. Lintas C. Tabolacci C. BRAF mutations in melanoma: Biological aspects, therapeutic implications, and circulating biomarkers. Cancers 2023 15 16 4026 10.3390/cancers15164026 37627054
    [Google Scholar]
  98. Fernandez M.F. Choi J. Sosman J. New approaches to targeted therapy in melanoma. Cancers 2023 15 12 3224 10.3390/cancers15123224 37370834
    [Google Scholar]
  99. Manap A.S.A. Lum Y.K. Ong L.H. Tang Y.Q. Gew L.T. Chia A.Y.Y. Perspective approaches on melanogenesis inhibition. Zhonghua Pifuke Yixue Zazhi 2021 39 1 1 12 10.4103/ds.ds_46_20
    [Google Scholar]
  100. Wang Y. Tian Y. Jia L. Xu S. Meng X. Nano-mediated strategy: Recent advance in the application of drug delivery systems in melanoma treatment and diagnosis. Biomed. Mater. 2024 19 5 052007 10.1088/1748‑605X/ad6dc3 39166400
    [Google Scholar]
  101. Babaei S. Fadaee M. Abbasi-kenarsari H. Shanehbandi D. Kazemi T. Exosome-based immunotherapy as an innovative therapeutic approach in melanoma. Cell Commun. Signal. 2024 22 1 527 10.1186/s12964‑024‑01906‑1 39482766
    [Google Scholar]
/content/journals/acamc/10.2174/0118715206380598250622182719
Loading
Lifileucel Therapy for Metastatic Melanoma: Advancements in Tumor-infiltrating Lymphocyte-based Immunotherapy
Bentham Science Publishers ; https://doi.org/10.2174/0118715206380598250622182719
/content/journals/acamc/10.2174/0118715206380598250622182719
/content/journals/acamc/10.2174/0118715206380598250622182719
Loading

Data & Media loading...


  • Article Type:     Review Article
Keywords: personalized medicine ; melanogenesis pathway ; tumor microenvironment ; tumor-infiltrating lymphocyte therapy ; Metastatic melanoma ; lifileucel

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test